New device improves healing of some ruptured aneurysms

American Stroke Association Meeting Report Abstract 112

February 11, 2015 Categories: Stroke News, Scientific Conferences & Meetings

Study Highlights:  

  • Among some patients, a new device called a HydroCoil® inserted into ruptured blood vessels in the brain significantly improved healing of the aneurysm compared to a standard device.
  • The device, which contains a gel that expands when it comes into contact with blood, was effective among patients with medium-sized aneurysms that had already ruptured.

Embargoed until 1:30 pm CT/2:30 pm ET, Wednesday, Feb. 11, 2015

This release is featured in a news conference at 1:30 p.m., Wednesday, Feb. 11 2015

NASHVILLE, Tenn., Feb. 11, 2015 – A new device inserted into small ruptured brain aneurysms significantly improved healing of ruptured aneurysms compared to a standard device, according to research presented at the American Stroke Association’s International Stroke Conference 2015.

Small aneurysms often cause no symptoms, but they can rupture and bleed into the area surrounding the brain or into the brain.

When bleeding occurs, immediate treatment is critical. One treatment for medium-sized ruptured aneurysms (5-10 millimeters) involves inserting a tiny platinum coil into the affected area to block blood flow and prevent the aneurysm from enlarging and rupturing.

In the study, researchers compared the effectiveness of the coils to HydroCoil®, a new device that combines a gel-like substance with the standard platinum coil. When the substance comes into contact with blood, the gel expands to block blood flow to the aneurysm.

Researchers analyzed data from 288 patients with medium-sized, ruptured aneurysms who were enrolled in a previous clinical study examining the effectiveness of HydroCoil® compared to standard coils. Seventy percent of patients were female and most were 55 years or younger.

Half the patients were randomly assigned to receive one of the two treatments, then researchers performed brain imaging studies 15-18 months later to determine whether the aneurysms had ruptured again or remained intact.

Among patients with ruptured, medium-sized aneurysms, the major recurrence rate was significantly lower – less than 20 percent – for those treated with HydroCoil® compared to the rates of those treated with bare platinum coils – more than 30 percent. An aneurysm rupture recurrence occurs when the aneurysm is not completely healed after treatment.

“We think that one of the reasons that the HydroCoil had better outcomes than the bare platinum coil in the ruptured aneurysms is that a ruptured aneurysm can have a little bit more of a complex or irregular shape, the expansion of the hydrogel likely allows for filling of some of these irregular outpouchings and rupture sites,” said Waleed Brinjikji, M.D., the study’s lead author and a radiologist at the Mayo Clinic in Rochester, Minn. “The advantage of the HydroCoil is that it will expand to fill in that irregular shape.”

Because the study included only a subgroup of patients, the results could be due to chance, researchers said. So further research is critical before changing the recommended treatment for aneurysms.

“We hope that these results help inform the development of future clinical trials,” Brinjikji said. “Since small aneurysms generally respond well to the bare platinum coils, and large aneurysms are difficult to treat with coils alone, clinicians should try to focus on enrolling patients with medium-sized, ruptured aneurysms in future trials. Only if these results can be replicated should they be used to change clinical management.”

In the United States, about 3-5 million people have an aneurysm each year.

Co-authors include Philip M. White, M.D.; Harry J. Cloft, M.D., Ph.D.; and David F. Kallmes, M.D. Author disclosures are on the abstract.

The original clinical study (HydroCoil® Endovascular aneurysm occlusion and Packing Study or HELPS) was funded by MicroVention.

Additional Resources:

###

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

Note: Actual presentation is 8:12 a.m. CT/9:12 a.m. ET, Thursday, Feb. 12, 2015, in Room 202.

For Media Inquiries:

AHA/ASA News Media in Dallas: (214) 706-1173

AHA/ASA News Media Office, Feb. 10-13,

at the Nashville Music City Center: (615) 345-6530

For Public Inquiries: (800) AHA-USA1 (242-8721)

heart.org and strokeassociation.org

Life is why we fund scientific breakthroughs that save and improve lives.